Naprosyn SR - Product Information
|Condition:||Ankylosing Spondylitis, Back Pain, Bursitis, Costochondritis, Chronic Myofascial Pain, Dysautonomia, Diffuse Idiopathic Skeletal Hyperostosis, Fever, Frozen Shoulder, Gout, Acute, Headache, Juvenile Rheumatoid Arthritis, Muscle Pain, Neck Pain, Osteoarthritis, Pain, Period Pain (Dysmenorrhea), Rheumatoid Arthritis, Sciatica, Spondylolisthesis, Tendonitis|
|Class:||Nonsteroidal anti-inflammatory agents|
|Ingredients:||naproxen, hypromellose, magnesium stearate , the colour, Sunset Yellow FCF |
(naproxen, sustained release)
CAS registry number: 2204531
NAPROSYN SR (naproxen, sustained release) is a non-steroidal anti-inflammatory drug (NSAID) with analgesic, anti-inflammatory and antipyretic properties.
Naproxen is a propionic acid derivative related to the arylacetic acid class of drugs. It is unrelated to salicylates and the corticosteroid hormones. The chemical name of naproxen is (+)-6-methoxy-alpha-methyl-2-naphthaleneacetic acid. It has a chemical formula of C14H14O3 and a molecular weight of 230.3. It is an odourless, white to off-white crystalline substance. It is lipid soluble, practically insoluble in water at low pH and freely soluble in water at high pH.
NAPROSYN SR is available as a sustained release tablet containing 750 mg or 1000 mg of naproxen. NAPROSYN SR tablets contain the excipients hypromellose, magnesium stearate, Sunset Yellow CI 15985 and purified water.
Naproxen has been shown to have anti-inflammatory properties when tested in human clinical studies. In addition, it has analgesic and antipyretic actions. It exhibits its anti-inflammatory effects even in adrenalectomised animals, indicating that its action is not mediated through the pituitary axis. It inhibits prostaglandin synthetase, as do other NSAIDs, however, the exact mechanism of its anti-inflammatory action is not known.
In humans naproxen is completely absorbed from the gastrointestinal tract after oral administration.
NAPROSYN SR tablets have a matrix formulation which remains intact during its transit through the gastrointestinal tract. When the tablet comes in contact with gastrointestinal fluids it forms a gelatinous layer which controls the rate of release of naproxen. Due to the controlled release, the peak plasma levels of naproxen are simultaneously reduced and delayed compared to standard NAPROSYN tablets, although the mean area under the plasma concentration-time curve of the SR formulation is equivalent to that of the standard formulation.
The lowest plasma naproxen concentrations attained with NAPROSYN SR tablets given once daily (i.e. 750 mg once daily or 1000 mg once daily) are equivalent to the lowest plasma naproxen concentration attained with the corresponding standard NAPROSYN tablet formulations given twice daily (i.e. 375 mg twice daily or 500 mg twice daily).
NAPROSYN SR tablets are unique compared to the standard NAPROSYN tablet in that the ‘peak’ to ‘trough’ plasma naproxen concentration ratio of 2.6 for NAPROSYN is reduced to 1.8 for the sustained release formulation; hence indicating that the administration of NAPROSYN SR tablets results in a more favourable pharmacokinetic profile.
Food does not alter the bioavailability of NAPROSYN SR tablets. However, ingestion of a high-fat meal prior to administration of NAPROSYN SR tablets does significantly increase the peak plasma concentration compared to that seen in fasted subjects. Food decreases the rate of transit of NAPROSYN SR tablets from the stomach to the intestines in both young and old adult patients. These results are unlikely to be of clinical significance.
Naproxen has a relatively small volume of distribution (0.09 ± 0.03 L/kg), which corresponds to about 10% of the body weight in humans. At therapeutic levels naproxen is greater than 99% albumin-bound.
The plasma concentration of naproxen increases proportionally with doses up to 500 mg twice daily. Larger doses result in a less than proportional increase due to accelerated renal clearance of disproportionately increased amounts of non-protein bound drug. However, whether this effect increases or decreases the toxicity of naproxen has not been established.
Steady-state plasma levels of naproxen are reached after 4 to 5 doses.
Naproxen enters synovial fluid and crosses the placenta. It has been found in the milk of lactating mothers at a concentration approximately 1% of that found in plasma.
Naproxen is metabolised in the liver to 6-0-desmethyl naproxen (approximately 28% of an IV dose).
Approximately 95% of the naproxen is excreted in the urine, primarily as naproxen (10%), 6-0-desmethyl naproxen (5%) or their conjugates. The rate of excretion of metabolites and conjugates has been found to coincide closely with the rate of naproxen clearance from the plasma. Small amounts, 5% or less, are excreted in the faeces.
The elimination half-life of naproxen is approximately 14 hours.
Pharmacokinetics in Special Populations
The pharmacokinetic profile of naproxen in children aged 5 -16 years is similar to that in adults.
Given that naproxen and its metabolites are primarily excreted by the kidney, the potential exists for accumulation in the presence of renal insufficiency. Elimination of naproxen is decreased in patients with severe renal impairment (creatinine clearance < 20 mL/min), in whom there is higher clearance of naproxen than estimated from the degree of renal impairment alone (see PRECAUTIONS – Renal Impairment).
NAPROSYN SR is indicated for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and for the relief of chronic pain states in which there is an inflammatory component.
NAPROSYN SR is contraindicated in patients:
- who are hypersensitive to naproxen or naproxen sodium or in whom acetylsalicylic acid (aspirin) or other non-steroidal anti-inflammatory/analgesic agents induce allergic manifestations, e.g. asthma, nasal polyps, rhinitis and urticaria. Severe anaphylactic-like reactions to naproxen have been reported in such patients
- with either active, or a history of, peptic or gastrointestinal ulceration, or chronic dyspepsia or active gastrointestinal bleeding or perforation, related to previous NSAIDs therapy
- with active, or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding).unrelated to previous NSAIDs therapy
- under 2 years of age since safety in this age group has not been established
- with severe heart failure
Cardiovascular Thrombotic Events
Observational studies have indicated that non-selective NSAIDs may be associated with an increased risk of serious cardiovascular events, including myocardial infraction and stroke, which may increase with dose or duration of use. Patients with cardiovascular disease or cardiovascular risk factors may also be at greater risk. To minimise the potential risk of an adverse cardiovascular event in patients taking an NSAID, especially in those with cardiovascular risk factors, the lowest effective dose should be used for the shortest possible duration (see DOSAGE AND ADMINISTRATION)
There is no consistent evidence to suggest that the concurrent use of aspirin mitigates the possible increased risk of serious cardiovascular thrombotic events associated with NSAID use.
Clinical trial and epidemiological data suggest that use of coxibs and some NSAIDs (particularly at high doses and long term treatment) may be associated with a small increased risk of arterial thrombotic events (e.g. myocardial infarction or stroke).
NSAIDs may lead to onset of new hypertension or worsening of pre-existing hypertension and patients taking anti-hypertensives with NSAIDs may have an impaired anti-hypertensive response. Caution is advised when prescribing NSAIDs to patients with hypertension. Blood pressure should be monitored closely during initiation of NSAID treatment and at regular intervals thereafter.
Fluid retention and oedema have been observed in some patients taking NSAIDs, therefore caution is advised in patients with fluid retention or heart failure.
All NSAIDs can cause gastrointestinal discomfort and rarely serious, potentially fatal, gastrointestinal effects such as ulcers, irritation, bleeding and perforation which may increase with dose or duration of use, but can occur at any time without warning. Upper gastrointestinal ulcers, gross bleeding or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3 - 6 months and in about 2 - 4% of patients treated for one year. These trends continue with longer duration of use, increasing the likelihood of developing a serious gastrointestinal event at some time during the course of therapy. However, even short term therapy is not without risk.
Caution is advised in patients with risk factors for gastrointestinal events who may be at greater risk of developing serious gastrointestinal events e.g. elderly, debilitated patients, those with a history of serious gastrointestinal events, smoking and alcoholism.
NSAIDs should be given with care to patients with a history of inflammatory bowel disease (ulcerative colitis; Crohn’s disease) as their condition may be exacerbated. Patients with a history of gastrointestinal toxicity, particularly when elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) particularly in the initial stages of treatment. When gastrointestinal bleeding or ulceration occurs in patients receiving NSAIDs, treatment should be withdrawn immediately. Physicians should warn patients about the signs and symptoms of serious gastrointestinal toxicity.
Studies to date have not identified any subset of patients not at risk of developing peptic ulcer and bleeding. However, elderly have an increased frequency of adverse effects to NSAIDs, especially gastrointestinal bleeding and perforation which may be fatal. Debilitated patients do not seem to tolerate ulceration or bleeding as well as others. Most of the fatal gastrointestinal events associated with NSAIDs occurred with the elderly and/or debilitated patients.
In patients with active peptic ulcer or inflammatory disease of the gastrointestinal tract and rheumatoid arthritis, an attempt might be made to treat the arthritis with a non-ulcerogenic drug.
Caution is advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding (see PRECAUTIONS - Interactions with Other Medicines). The concurrent use of aspirin and NSAIDs also increase the risk of serious gastrointestinal adverse events.
Patients with risk factors should commence treatment on the lowest dose available.
There have been reports of impaired renal function, renal failure, acute interstitial nephritis, haematuria, proteinuria, renal papillary necrosis, and occasionally nephritic syndrome associated with NAPROSYN SR.
NAPROSYN SR should not be given to patients with creatinine clearance less than 30 mL/minute because accumulation of naproxen metabolites has been seen in such patients.
As with other NSAIDs, NAPROSYN SR should be used with caution in patients with impaired renal function, or a history of kidney disease because naproxen is an inhibitor of prostaglandin synthesis. Caution should be observed in patients with conditions leading to a reduction in blood volume and/or renal blood flow as prostaglandins have a supportive role in the maintenance of renal perfusion. In these patients, administration of NAPROSYN SR or other NSAIDs may cause a dose-dependant reduction in renal prostaglandin formation and may precipitate overt renal decompensation or failure. Patients at greatest risk are those with impaired renal function, hypovolaemia, heart failure, liver dysfunction, salt depletion, those taking diuretics, angiotensin coverting enzyme inhibitors or angiotensin receptor blockers and the elderly. Discontinuation of NAPROSYN SR is usually followed by recovery to the pre-treatment state; however, serious adverse events may persist. NAPROSYN SR should be used with great caution in such patients and the monitoring of serum creatinine and/or creatinine clearance is advised and patients should be adequately hydrated . A reduction of daily dosage should be considered to avoid the possibility of excessive accumulation of naproxen metabolites in these patients.
Haemodialysis does not decrease the plasma concentration of naproxen because of the high degree of its protein binding.
Naproxen decreases platelet aggregation and prolongs bleeding time. This effect should be kept in mind when bleeding times are being determined. (See PRECAUTIONS – Effects on Laboratory Tests).
Patients who have coagulation disorders or are receiving drug therapy that interferes with haemostasis should be carefully observed if NAPROSYN SR is administered. Patients at high risk of bleeding and those on anticoagulation therapy (e.g. heparin or dicoumarol derivatives) may be at increased risk of bleeding if given NAPROSYN SR concurrently. Therefore, benefits of prescribing NAPROSYN SR should be weighed against these risks.
Patients with initial haemoglobin values of 10 grams or less, and who are to receive long-term therapy should have haemoglobin values determined frequently.
Patients on other drugs such as hydantoins, sulfonamides, sulfonylureas or methotrexate should be observed for increased effect or toxicity (see PRECAUTIONS – Interaction with Other Medicines).
Severe Skin Reactions
NSAIDs may very rarely cause serious cutaneous adverse events such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be fatal and occur without warning. These serious adverse events are idiosyncratic and are independent of dose or duration of use. Patients should be advised of the signs and symptoms of serious skin reactions and to consult their physician at the first appearance of a skin rash or any other sign of hypersensitivity.
Hypersensitivity reactions may occur in susceptible individuals. Anaphylactic (anaphylactoid) reactions may occur both in patients with, and without, a history of hypersensitivity or exposure to aspirin or other NSAIDs or naproxen-containing products. They may also occur in individuals with a history of angioedema, bronchospastic reactivity (e.g. asthma), rhinitis and nasal polyps. Anaphylactoid reactions, like anaphylaxis, may have a fatal outcome.
Bronchospasm may be precipitated in patients suffering from, or with a history of, asthma or allergic disease or aspirin sensitivity.
As with other NSAIDs borderline elevations of one or more liver function tests may occur in up to 15% of patients. These abnormalities may progress, may remain essentially unchanged, or may resolve with continued therapy. The ALT test is probably the most sensitive indicator of liver dysfunction. Meaningful elevations (three times the upper limit of normal) of ALT or AST occurred in controlled clinical trials in less than 1% of patients. A patient with symptoms and/or signs suggesting hepatic dysfunction, or in whom an abnormal hepatic test has occurred, should be evaluated for evidence of the development of more severe hepatic reactions while on therapy with NAPROSYN SR.
Hepatic abnormalities may be the result of hypersensitivity or direct toxicity.
Severe hepatic reactions, including jaundice and cases of fatal hepatitis, have been reported with naproxen as with other NSAIDs. Cross reactivity has been reported. Although such reactions are rare, if abnormal hepatic tests persist or worsen, if clinical signs and symptoms consistent with hepatic disease develop, or if systemic manifestations occur (e.g. eosinophilia, rash, etc.), NAPROSYN SR should be discontinued.
Chronic alcoholic hepatic disease and potentially other forms of cirrhosis reduce the total plasma concentration of naproxen; however, the plasma concentration of unbound naproxen is increased. The implication of this finding for naproxen dosing is unknown.
In patients with impaired hepatic function, the lowest effective dose is recommended.
The antipyretic, anti-inflammatory and analgesic effects of naproxen may mask the usual signs or symptoms of infection.
Adverse ophthalmological effects have been observed with NSAIDs. In rare cases, adverse ocular disorders including papillitis, retrobulbar optic neuritis and papilloedema have been reported in users of NSAIDs including NAPROSYN SR, although a cause-and-effect relationship cannot be established; accordingly, patients who develop visual disturbances during treatment with NAPROSYN SR should have an ophthalmological examination.
Fluid Retention and Oedema
Peripheral oedema has been observed in some patients taking NAPROSYN SR or other NSAIDs. Although sodium retention has not been reported in metabolic studies, it is possible that patients with compromised cardiac function may be at greater risk when taking naproxen. For this reason, naproxen should be used with caution in patients with fluid retention, hypertension or heart failure.
Use in Pregnancy
PREGNANCY CATEGORY: C
NSAIDs inhibit prostaglandin synthesis and when given during the latter part of pregnancy, may cause closure of the foetal ductus arteriosus, prolong labour and delay birth. During the last few days before expected birth, agents with an inhibitory effect on prostaglandin synthesis should be avoided. Continuous treatment with NSAIDs during the last month of pregnancy should only be given when clearly indicated.
NAPROSYN SR should only be administered during pregnancy if the benefit justifies the potential risk.
The use of NAPROSYN SR, as with any drug known to inhibit cyclooxygenase/prostaglandin synthesis, may impair fertility and is not recommended in women attempting to conceive. In women who have difficulty conceiving or are undergoing investigation of infertility, withdrawal of naproxen should be considered.
Use in Lactation
Naproxen has been found in the milk of lactating mothers at a concentration approximately 1% of that found in plasma. As the effect of naproxen in the newborn is not known, the use of NAPROSYN SR in lactating mothers is not recommended.
NAPROSYN SR is not recommended in children under 5 years of age as the safety and efficacy in this population has not been established.
Use in Elderly
The lowest effective dose is recommended in elderly patients.
Studies indicate that although the total plasma concentration of naproxen is unchanged, the unbound plasma fraction of naproxen is increased in the elderly.
NAPROSYN SR is not recommended in elderly patients with hepatic or renal impairment.
Interactions with Other Medicines
Concomitant administration of sucralfate or cholestyramine can delay the absorption of naproxen, but does not affect its extent. Antacids have a variable effect on absorption.
Combination of naproxen-containing products and other NSAIDs, including cyclooxygenase-2 (COX-2) selective inhibitors, is not recommended, because of the cumulative risks of inducing serious NSAID-related adverse events.
Naproxen is highly bound to plasma albumin; thus naproxen has a theoretical potential for interaction with other albumin-bound drugs, for example, warfarin or bishydroxycoumarin may be displaced and induce excessively prolonged prothrombin times.. Similarly, patients receiving hydantoins, sulfonamides or sulfonylureas should be observed for increased effect or toxicity(see PRECAUTIONS – Haematological).
The concurrent use of NSAIDs and warfarin has been associated with severe, sometimes fatal, haemorrhage. The exact mechanism of the interaction between NSAIDs and warfarin is unknown, but may involve enhanced bleeding from NSAID-induced gastrointestinal ulceration, or an additive effect of anticoagulation by warfarin and inhibition of platelet function by NSAIDs. NAPROSYN SR should be used in combination with warfarin only if absolutely necessary, and patients taking this combination of drugs should be closely monitored.
Anticoagulants/ Anti-platelet Agents
Patients who have coagulation disorders or are receiving drug therapy that interferes with haemostasis should be carefully observed if naproxen is administered. Patients on full anticoagulation therapy (e.g. heparin or dicoumarol derivatives) may be at increased risk of bleeding if given naproxen concurrently. Thus, the benefits should be weighed against these risks.
There is an increased risk of gastrointestinal bleeding when anti-platelet agents are combined with NSAIDs.
Selective Serotonin Reuptake Inhibitors (SSRIs)
There is an increased risk of gastrointestinal bleeding when SSRIs are combined with NSAIDs.
If steroid dosage is reduced or eliminated during NAPROSYN SR therapy, the steroid dosage should be reduced slowly and the patients must be observed closely for any evidence of adverse effects, including adrenal insufficiency and exacerbation of symptoms of underlying disease.
Probenecid significantly prolongs the half-life of naproxen (from 14 to 37 hrs). This is associated with a decrease in conjugated metabolites and an increase in 6-0-desmethyl naproxen.
Concomitant administration of naproxen and methotrexate should be done with caution, because naproxen has been reported among other NSAIDs to reduce the tubular secretion of methotrexate in animal models, and thus possibly increasing the toxicity of methotrexate.
Naproxen and other NSAIDs can reduce the anti-hypertensive effect of beta-blockers, angiotensin converting enzyme inhibitors (ACE inhibitors), and angiotensin receptor blockers (ARBs).
As with other NSAIDs, naproxen may inhibit the natriuretic effect of frusemide.
Inhibition of renal lithium clearance leading to increases in plasma lithium concentrations has been reported.
Sodium bicarbonate may enhance the rate of naproxen absorption.
In vitro studies have shown that naproxen may interfere with the metabolism of zidovudine, resulting in higher zidovudine plasma levels. Therefore, to avoid the potential side effects associated with increased zidovudine plasma levels, dose reduction should be considered.
Concomitant use of NSAIDs with ACE inhibitors or angiotensin receptor blockers may increase the risk of renal dysfunction, especially in patients with pre-existing poor renal function (see PRECAUTIONS).
Combination use of ACE-inhibitors or angiotensin receptor antagonists, anti-inflammatory drugs and thiazide diuretics.
The use of an ACE inhibiting drug (ACE-inhibitor or angiotensin receptor antagonist), an anti-inflammatory drug (NSAID or COX-2 inhibitor) and a thiazide diuretic at the same time (triple whammy) increases the risk of renal impairment. This includes use in fixed-combination products containing more than one class of drug. Combined use of these medications should be accompanied by increased monitoring of serum creatinine, particularly at the initiation of the combination. The combination of drugs from these three classes should be used with caution particularly in elderly patients or those with pre-existing renal impairment.
Effects on Laboratory Tests
Naproxen decreases platelet aggregation and prolongs bleeding time. This effect should be considered when bleeding times are determined.
NAPROSYN SR may artefactually interfere with some tests for 17-ketogenic steroid and may interfere with some urinary assays for 5-hydroxy-indoleacetic acid (5HIAA). 17-hydroxycorticosteroid measurements (Porter/Silber test) do not appear to be altered.
Naproxen therapy should be temporarily discontinued for at least 72 hours before testing adrenal function.
Effects on Ability to Drive and Operate Machinery
Some patients may experience drowsiness, dizziness, vertigo, insomnia or depression with the use of NAPROSYN SR. If patients experience these or similar undesirable effects, they should exercise caution in carrying out activities that require alertness.
Adverse effects reported in controlled clinical trials in 960 patients treated for rheumatoid arthritis and osteoarthritis are listed below. In general, these adverse effects were reported 2 to 10 times more frequently than they were in studies of 962 patients treated for mild to moderate pain.
Incidence between 3% and 9%
Gastrointestinal: The most frequently reported adverse effects were related to the gastrointestinal tract. These were: constipation, heartburn, abdominal pain, nausea
Central Nervous System: headache, dizziness, drowsiness
Dermatologic: itching (pruritis), skin eruption, ecchymoses
Special Senses: tinnitus
Cardiovascular: oedema, dyspnoea
Incidence between 1% and less than 3%
Gastrointestinal: dyspepsia, diarrhoea, stomatitis
Central Nervous System: light-headedness, vertigo
Dermatologic: sweating, purpura
Special Senses: hearing disturbances, visual disturbances
Incidence less than 1%
PROBABLE CAUSAL RELATIONSHIP:
The following adverse effects were reported less frequently than 1% during controlled clinical trials and through post-marketing reports. A causal relationship probably exists between naproxen and these adverse effects.
Gastrointestinal: abnormal liver function tests, gastrointestinal bleeding, haematemesis, jaundice, melaena, peptic ulceration with bleeding and/or perforation, non-peptic gastrointestinal ulceration, vomiting, ulcerative stomatitis, colitis, fatal hepatitis
Renal: glomerular nephritis, haematuria, interstitial nephritis, nephrotic syndrome, renal disease, renal papillary necrosis, renal failure, hyperkalaemia
Haematologic: eosinophilia, granulocytopenia, leukopenia, thrombocytopenia
Central Nervous System: depression, dream abnormalities, inability to concentrate, insomnia, malaise, myalgia, muscle weakness, aseptic meningitis
Dermatologic: porphyria cutanea tarda, epidermolysis bullosa, alopecia, skin rashes, epidermal necrolysis, erythema multiforme, Stevens-Johnson syndrome (SJS), photosensitivity reactions including rare cases in which the skin resembles porphyria cutanea tarda (pseudoporphyria) or epidermolysis bullosa
Special Senses: hearing impairment
Cardiovascular: vasculitis, congestive heart failure
General: menstrual disorders, pyrexia (chills and fever), eosinophilic pneumonitis, anaphylactoid reactions (see PRECAUTIONS – Anaphylactic Reactions)
CAUSAL RELATIONSHIP UNKNOWN:
Other reactions have been reported in circumstances in which a causal relationship could not be established. Although rarely reported, the physician should be alerted to these.
Haematologic: agranulocytosis, aplastic anaemia, haemolytic anaemia
Central and Peripheral Nervous System: cognitive dysfunction, convulsions, paraesthesia
Dermatologic: urticaria, photosensitivity
Mouth and Throat: sore throat
General: angioneurotic oedema, hyperglycaemia, hypoglycaemia, hyperkalaemia
Reproductive: female infertility
The following adverse effects have been reported with NSAIDs and NAPROSYN SR:
Gastrointestinal: inflammation, peptic ulcers, ulceration, perforation and obstruction of the upper and lower gastrointestinal tract, gastrointestinal bleeding (sometimes fatal, particularly in the elderly), heartburn, nausea, Oesophagitis, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, non-peptic gastrointestinal ulceration, melaena, haematemesis, stomatitis, ulcerative stomatitis, exacerbation of ulcerative colitis and Crohn’s disease, pancreatitis, gastritis
Infection: aseptic meningitis
Blood and Lymphatic System Disorders: agranulocytosis, aplastic anaemia, eosinophilia, haemolytic anaemia, leucopenia, thrombocytopenia
Immune System Disorders: anaphylactoid reactions
Metabolic and Nutrition Disorders: hyperkalaemia
Psychiatric Disorders: depression, dream abnormalities, insomnia
Nervous System Disorders: dizziness, drowsiness, headache, light-headedness, retrobulbar optic neuritis, convulsions, cognitive dysfunction, inability to concentrate
Eye Disorders: visual disturbances, corneal opacity, papillitis, papilloedema
Ear and Labyrinth Disorders: hearing impairment, hearing disturbances, tinnitus, vertigo
Cardiac Disorders: palpitations, cardiac failure, congestive heart failure
Vascular Disorders: hypertension, vasculitis
Respiratory, Thoracic and Mediastinal Disorders: dyspnoea, pulmonary oedema, asthma, eosinophilic pneumonitis
Hepatobiliary Disorders: hepatitis, jaundice
Skin and Subcutaneous Tissue Disorder: ecchymoses, itching (pruritus), purpura, skin eruptions, sweating, alopecia, epidermal necrolysis, very rarely toxic epidermal necrolysis (TEN), erythema multiforme, bullous reactions (including SJS), erythema nodosum, fixed drug eruption, lichen planus, pustular reaction, skin rashes, systemic lupus erythematosus (SLE), urticaria, photosensitivity reactions, including rare cases resembling porphyria cutanea tarda (pseudoporphyria) or epidermolysis bullosa or angioneurotic oedema
If skin fragility, blistering or other symptoms suggestive of pseudoporphyria occur, treatment should be discontinued and patient monitored.
Musculoskeletal and Connective Tissue Disorders: myalgia, muscle weakness
Renal and Urinary Disorders: haematuria, interstitial nephritis, nephritic syndrome, renal disease, renal failure, renal papillary necrosis
Reproductive System: female infertility
General Disorders: oedema, thirst
Investigations: abnormal liver function tests, raised serum creatinine
Dosage And Administration
After assessing the risk/benefit ratio in each individual patient, the lowest effective dose for the shortest possible duration should be used.
The total required daily dose of naproxen can be achieved by the administering the appropriate single daily dose i.e. NAPROSYN SR 750 mg or NAPROSYN SR 1000 mg.
The total daily dose of naproxen should not exceed 1000 mg. NAPROSYN SR tablets should be taken whole and not chewed.
NAPROSYN SR TABLETS ARE NOT INTENDED FOR PATIENTS REQUIRING SHORT-TERM TREATMENT FOR ACUTE INDICATIONS.
Significant overdose of the medicine may be characterised by dizziness, drowsiness, epigastric pain, abdominal discomfort, indigestion, transient alterations in liver function, hypoprothrombinaemia, renal dysfunction, metabolic acidosis, apnoea, disorientation, nausea or vomiting. A few patients have experienced seizures, but it is unclear if these were causally related to naproxen. It is not known what dose of naproxen would be life-threatening.
Gastrointestinal bleeding may occur. Hypertension, acute renal failure, respiratory depression and coma may occur after the ingestion of NSAIDs, and may occur following an overdose.
Anaphylactoid reactions have been reported with therapeutic ingestion of NSAIDs, and may occur following an overdose.
Patients should be managed by symptomatic and supportive care following NSAIDs overdose. There are no specific antidotes. Prevention of further absorption (e.g. activated charcoal) may be indicated in symptomatic patients seen within 4 hours of ingestion or following a large overdose. Forced diuresis, alkalinization of urine, haemodialysis or haemoperfusion may not be useful due to high protein binding.
Due to the sustained-release characteristic of NAPROSYN SR tablets, it should be expected that naproxen will continue to be absorbed for up to 16 hours after ingestion.
Contact the Poisons Information Centre for advice on management of overdosage.
Presentation And Storage Conditions
NAPROSYN SR 750 mg tablets are available as uncoated, oval, peach coloured tablets, embossed “NPR SR-750” on one side, in packs of 28s.
NAPROSYN SR 1000 mg tablets are available as uncoated, oval, peach coloured tablets, embossed “NPR SR-1000” on one side, in packs of 28s.
Store below 30°C. Protect from light.
ROCHE PRODUCTS PTY LIMITED
ABN 70 000 132 865
4-10 Inman Road
Dee Why NSW 2099
Date Of First Inclusion In The Australian Register Of Therapeutic Goods (the ARTG):
19 July 1991
TGA Product Information Approval Date:
25 January 2008
Date Of Most Recent Amendment:
15 August 2012